{"summary": "Author presents due diligence on OTC biotech RMTG, citing explosive revenue growth, minimal dilution, and a peptide/regenerative medicine ecosystem as reasons for a starter long position.", "reason": "The author expresses a directional investment judgment (starter position) and provides fundamental reasons (revenue growth, low dilution, and market expansion) for the thesis.", "ideas": [{"symbol": "RMTG", "direction": "long", "thesis": "Author took a starter position in OTC biotech RMTG, whose Cellgenics peptide division and ISSCA physician-training ecosystem are riding the post-Ozempic regenerative medicine boom. Revenue jumped from $5.1m for all of 2025 to $6.66m in H1 2026, with Q2 at $4.02m versus $984k a year earlier, driven by both product sales and physician training, while dilution stayed under 5% over the past year. The author cites debt and interest expense as the main risk and is still evaluating before taking a larger position. Chart shows higher highs and lows with accumulation in the .08 range.", "thesis_short": "RMTG revenue surge, low dilution, starter long", "quote": "I took a starter position here earlier this week, and as I continue to do my DD, it's difficult to find many glaring negatives for an OTC company.", "confidence": 0.75, "sentiment": 0.7, "timeframe": "unspecified"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}